Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.32 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156419 | 0.98 | CYP11B1 (0.48) | CYP11B1CYP11B2LMNAHSD17B10SCN2A | |
| SCHEMBL27883754 | 0.77 | CYP11B1 (0.44) | CYP11B1CYP11B2LMNAHSD17B10SCN2A | |
| Bromide SCHEMBL6154952 | 0.76 | LMNA (0.59) | LMNAHSD17B10SCN2ATSHRKDM4E | |
| SCHEMBL6155294 | 0.73 | LMNA (0.60) | LMNAHSD17B10SCN2ATSHRKDM4E | |
| SCHEMBL27972665 | 0.73 | CYP11B1 (0.41) | CYP11B1CYP11B2LMNAHSD17B10SCN2A | |
| SCHEMBL27575532 | 0.73 | ALDH1A1 (0.59) | CYP11B1CYP11B2LMNAHSD17B10TSHR | |
| SCHEMBL6155334 | 0.73 | CYP11B1 (0.36) | CYP11B1CYP11B2LMNAHSD17B10CYP3A4 | |
| SCHEMBL6158208 | 0.73 | CYP11B1 (0.36) | CYP11B1CYP11B2LMNAHSD17B10KDM4E | |
| SCHEMBL6155373 | 0.72 | LMNA (0.36) | CYP11B1CYP11B2LMNAHSD17B10TSHR | |
| SCHEMBL6724480 | 0.71 | SIGMAR1 (0.46) | CYP11B1CYP11B2LMNAHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0940139-B1 | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers | SCION PHARMACEUTICALS INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6071969-A | ADMINISTERING AMINOGUANIDINE DERIVATIVE TO MAMMAL FOR TREATING OR PREVENTING DISEASE OF NERVOUS SYSTEM IN WHICH PATHOPHYSIOLOGY OF DISORDER INVOLVES EXCESSIVE RELEASE OF OF NEUROTRANSMITTER FROM NEURONAL CELLS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0584088-B1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE RES (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5837737-A | MODULATOR OF NEUROTRANSMITTERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5741661-A | SCREENING ASSAY | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-04-21 | — | — | US | disclosed |
| US-5681861-A | BLOCKING VOLTAGE SENSITIVE SODIUM AND CALCIUM CHANNELS IN MAMMALIAN NERVE CELLS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| US-5677348-A | ADMINISTERING AN ANTAGONIST OF RELEASING ENDOGENOUS GLUTAMATE OR NEUROTRANSMITTER RELEASE MODULATORS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-10-14 | — | — | US | disclosed |
| US-5672608-A | INHIBIT RELEASE OF NEUROTRANSMITTERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5670519-A | NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5652269-A | MODULATION OF NEUROTRANSMITTER RELEASE, NEUROPROTECTIVE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| US-5637623-A | CENTRAL NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-06-10 | — | — | US | disclosed |
| US-5622968-A | ADMINISTERING TO BLOCK VOLTAGE SENSITIVE CALCIUM CHANNELS OF MAMMALIAN NEURONAL CELLS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5614630-A | NEUROTRANSMITTER RELEASE MODULATOR | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-03-25 | — | — | US | disclosed |
| US-5403861-A | Treating or preventing nerve cell death | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1995-04-04 | — | — | US | disclosed |